


Journal of Visualized Experiments

Using facial electromyography to assess facial muscle reactions to experienced and observed affective touch in humans --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59228R2
Full Title:	Using facial electromyography to assess facial muscle reactions to experienced and observed affective touch in humans
Keywords:	Facial electromyography; C-tactile; affective touch; affect; emotion; emotional reactivity; corrugator; social touch
Corresponding Author:	Leah Mayo, PhD Linköping University Linköping, Non-US or Canadian Address SWEDEN
Corresponding Author's Institution:	Linköping University
Corresponding Author E-Mail:	leah.mayo@liu.se
Order of Authors:	Anbjørn Ree India Morrison Håkan Olausson Uta Sailer Markus Heilig Leah M. Mayo, PhD
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Linköping, Sweden

Dr. Leah M. Mayo
Center for Social and Affective Neuroscience
Linköping University
SE-58431 Linköping, Sweden

Dr. Aaron Berard
Editor
Journal of Visualized Experiments



November 28, 2018

Dr. Berard,

We are pleased to submit the revised version of our manuscript, "Using facial electromyography to assess facial muscle reactions to experienced and observed touch in humans" for publication in the *Journal of Visualized Experiments*.

We are grateful to the editor and reviewers for their thorough and constructive feedback. As requested, we have made extensive changes to the manuscript, including a more directed protocol, a more detailed results section, and a more thorough discussion. We have also included additional figures and a table including details of our tasks. Most importantly, we have included enough information to ensure that others can replicate our experimental setup in their own endeavors to explore affective touch using facial electromyography.

We hope that the editor and reviewers find our revisions to be satisfactory on all accounts, and will be happy to provide further clarifications if needed.

Sincerely,

Leah M. Mayo
(on behalf of all authors)

TITLE:

Using Facial Electromyography to Assess Facial Muscle Reactions to Experienced and Observed Affective Touch in Humans

AUTHORS & AFFILIATIONS:

Anbjørn Ree¹, India Morrison², Håkan Olausson², Uta Sailer¹, Markus Heilig², Leah M. Mayo²

¹Department of Behavioral Sciences in Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Norway

²Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine, Linköping University, Sweden

Corresponding Author:

Dr. Leah M. Mayo (leah.mayo@liu.se)

Email Addresses of Co-Authors:

Anbjørn Ree (anbjorn.ree@medisin.uio.no)

India Morrison (india.morrison@liu.se)

Håkan Olausson (hakan.olausson@liu.se)

Uta Sailer (uta.sailer@medisin.uio.no)

Markus Heilig (markus.heilig@liu.se)

KEYWORDS:

facial electromyography, C-tactile afferents, affective touch, affect, emotion, corrugator

SUMMARY:

We describe a protocol to assess facial muscle activity in response to experienced and observed tactile stimulation using facial electromyography.

ABSTRACT:

“Affective” touch is believed to be processed in a manner distinct from discriminatory touch and to involve activation of C-tactile (CT) afferent fibers. Touch that optimally activates CT fibers is consistently rated as hedonically pleasant. Patient groups with impaired social-emotional functioning also show disordered affective touch ratings. However, relying on self-reported ratings of touch has many limitations, including recall bias and communication barriers. Here, we describe a methodological approach to study affective responses to touch via facial electromyography (EMG) that circumvents the reliance on self-report ratings. Facial EMG is an objective, quantitative, and non-invasive method to measure facial muscle activity indicative of affective responses. Responses can be assessed across healthy and patient populations without the need for verbal communication. Here, we provide two separate datasets demonstrating that CT-optimal and non-optimal touch elicit distinct facial muscle reactions. Moreover, facial EMG responses are consistent across stimulus modalities, e.g. tactile (experienced touch) and visual (observed touch). Finally, the temporal resolution of facial EMG can detect responses on timescales that supersede that of verbal reporting. Together, our data suggest that facial EMG is

a suitable methodology for use in affective tactile research that can be used to supplement, or in some cases, supplant, existing measures.

INTRODUCTION:

C-tactile (CT) afferents are proposed to convey the affective component of touch, which can be distinguished from the discriminative aspects of touch processed via A β fibers^{1,2}. CT-mediated affective touch is believed to play an integral role in social affiliative behaviors³, leading to the “skin as a social organ” hypothesis⁴. Physical^{5,6}, developmental⁷, and psychiatric^{8,9} factors can influence CT-mediated touch processing. Thus, establishing an objective measure to quantify affective reactions to CT-relevant touch is critical to allow for comparisons across populations.

In recent years, much insight has been gained regarding the characteristics of CT afferents. These unmyelinated afferents demonstrate an inverted U-shaped firing frequency, with velocities of 1-10 cm/s (“CT-optimal”) eliciting the greatest frequency and both greater (“fast non-optimal”) or lesser (“slow non-optimal”) velocities eliciting reduced firing¹⁰. CT firing frequency correlates with self-reported ratings of touch “pleasantness”, producing a similar inverted U-shaped curve in pleasantness ratings¹⁰. Moreover, CT-afferents also respond most robustly to stimuli close to skin temperature¹¹. These fibers also show distinct conduction speeds. The unmyelinated CT afferents are slower² and thus the volley of afferent input to the cortex shows a temporal lag when compared to the speed of the faster, myelinated A β fibers^{1,12}. Affective and discriminative touch can also be distinguished on a neural level. While both types of touch activate overlapping somatosensory areas, affective touch is more likely to activate the posterior insula, while discriminative touch activates sensorimotor areas¹³⁻¹⁶. This activation pattern is consistent whether the touch is directly experienced or merely observed¹⁷, suggesting that affective touch is not just a “bottom-up” process driven by physical activation of CT afferents, but also involves “top-down” integration of multimodal sensory processing.

Situations in which CT processing is deficient or otherwise atypical has also provided insight into the functional significance of these afferents. In a unique patient group with a heritable mutation affecting the nerve growth factor β gene, there is a reduction in the density of thin and unmyelinated nerve fibers, including CT afferents. Compared to healthy controls, these patients report touch at CT-optimal velocities as less pleasant⁵. The converse scenario is also true; patients who lack myelinated A β fibers are able to retain a faint sensation of pleasant touch carried by the still intact CT afferents⁶. Abnormal affective touch processing is not just confined to instances of physical changes in CT-afferents. Across patient and healthy populations, those higher on the spectrum of autistic traits reported reduced pleasantness ratings of touch⁸. Psychiatric patients also demonstrate reduced hedonic ratings of affective touch, with a history of childhood maltreatment as one of the most consistent predictors of dysregulated affective touch awareness⁸. Dysregulation in the CT-based affective touch system in anorexia nervosa has also been reported⁹. Thus, both physical and psychological factors can influence affective touch processing, and as such, it is imperative to establish methodologies that can be applied to all individuals in an equitable and comparable manner.

Insights into normo-typical and dysregulated affective processing have the opportunity to

provide a more nuanced picture of many patient groups. However, one potential limitation of affective touch research is the necessity of self-reported ratings. At times, self-report can be unreliable¹⁸ and subject to recall bias¹⁹. Inquiries of self-report can psychologically remove a participant from the current setting, limiting the ecological validity of the responses and removing them temporally from the experience²⁰. Moreover, self-report relies on a firm understanding of language and semantics, making cross-cultural and developmentally diverse (e.g. infant and toddler-aged individuals) comparisons challenging. For instance, individuals with an autism spectrum diagnosis frequently show distinct behavioral responses to touch²¹, but can also have difficulties in communicating verbally²². Thus, finding non-invasive methods to measure responses to touch that circumvent a reliance on self-report may translate, at least, to a better understanding of the mechanisms of affective touch, and at most, novel insights into dysregulation of social processing in patient populations.

Facial electromyography (EMG) is a suitable candidate to objectively assess affective responses to touch. It has been used to measure valence-specific reactions to visual²³, audio-visual²⁴, olfactory²⁵, and gustatory²⁶ stimuli. Facial EMG is a safe and non-invasive method consisting of surface electrodes that adhere to the face²⁷. These surface electrodes record facial muscle activity continuously in real-time with time scale sensitivity in the tens of milliseconds. Of particular interest is the corrugator supercilii (“corrugator”), which is activated when furrowing the brow and relaxes during a smile. As a result, corrugator activity has a linear relationship with affective valence, with increased response to negative stimuli and decreased activity in response to positive stimuli²⁸. In addition, the zygomaticus major (“zygomatic”) is the muscle activated as the corners of the mouth pull up into a smile. The zygomatic displays a “J-shaped” activation pattern with positive stimuli eliciting the greatest response, and the most negative stimuli eliciting a greater response than neutral stimuli²⁸. Facial EMG recordings of these muscles can even be observed when stimuli are presented outside conscious awareness or when individuals are explicitly trying to suppress their reactions^{29,30}. Importantly, facial EMG can be used alone or in combination with self-report ratings or other physiological recordings. Thus, it is an ideal methodology to assess affective reactions to tactile stimulation^{31,32}.

In sum, facial EMG can be combined with self-report ratings to determine how CT-optimal tactile stimulation influences facial muscle activity as a potential indicator of affective response. One can take advantage of the velocity-dependent firing frequency of CTs to apply touch at CT-optimal and non-optimal velocities, and touch can be applied both to the CT-rich arm and the putatively CT-lacking palm. Comparisons can be made across modalities to determine whether affective responses to touch require direct stimulation or can be elicited via mere observation, suggestive of shared processing across sensory modalities. Finally, upon establishing facial EMG as a suitable methodology to study affective reactions to affective touch, researchers can then explore how affective touch processing may be influenced by various interventions (e.g., drug administration; stress exposure), how it changes throughout development⁷, how it is influenced by the relationship of the interactants³³, and whether it is dysregulated in clinical populations⁸.

PROTOCOL:

This protocol is based on Mayo et al.³¹ (Experiment 1) and Ree et al.³² (Experiment 2). Ethical approval was granted by the Regional Ethical Review Board, Linköping, Sweden (Experiment 1) and the local ethical committee at the Department of Psychology, University of Oslo, Norway (Experiment 2).

1. Participant screening and preparation

1.1. Recruit participants who lack tactile or uncorrected visual disturbances and are free of any neurological or psychiatric disorder, unless a specific patient population is being recruited.

1.2. Ensure that participants are fully able to understand task instructions (e.g., fluent in the language that tasks are administered).

1.3. If including more than one task (e.g. Experienced, Observed), ensure that task order is counterbalanced across participants, stratifying for gender, age, or other distinguishing factors.

2. Stimuli and task construction

NOTE: See **Table 1** for experimental design.

2.1. Experienced touch task (Experiments 1 and 2)

2.1.1. Create trials such that they consist of a baseline period, touch administration, and self-report ratings, all separated by jittered ITIs.

2.1.1.1. Baseline periods consist of a blank screen, fixation cross, or other neutral scene prior to tactile stimulation.

2.1.1.2. Tactile stimulation is followed by a short (e.g. 1-2 s) ITI, then self-report ratings are obtained.

2.1.1.3. A jittered inter-trial interval (ITI; e.g. 6-7 s) follows self-report ratings to allow muscle activity to return to baseline levels before the next trial begins.

2.1.2. Use either audio (Experiment 1³¹) or visual (Experiment 2³²) cues to ensure that touch is delivered at the appropriate velocity.

2.1.2.1. To use audio cues, have cues delivered to headphones worn by the experimenter to track the pace of the stimulation using a metronome. Distinguish velocities using tones of differing pitches (or other distinguishing audio cue, e.g., a cue saying “10 cm/s”) that precede the stimulation cues.

2.1.2.2. To use visual cues, display cues on a tablet only in view of the experimenter. Use a moving bar to track velocity of touch administration.

2.1.3. Prior to the start of the study, practice to ensure that touch is delivered at the appropriate velocity and a consistent pressure. To do so, apply brushstrokes to the scale in a similar manner as to the participant. The scale readout is used to determine if the pressure changes throughout touch administration. For instance, a pressure of 0.4 N would read as 40 g on the scale.

2.2. Observed touch task (Experiment 1)

2.2.1. Ensure that videos of touch administration are of similar length, regardless of velocity.

2.2.1.1. Include both CT-optimal (1-10 cm/s) and non-optimal (less than 1 cm/s or more than 10 cm/s) velocities.

2.2.2. Start trials with a fixation cross or other neutral condition followed by video.

NOTE: Videos contain touch delivered to CT-rich hairy skin (arm), CT-lacking glabrous skin (palm), and a non-social condition in which touch is delivered to a fake wooden arm (Fig. 2; see supplemental videos).

2.2.2.1. After a 1-2 s ITI, obtain self-report ratings.

2.2.2.2. Allow another 6-7 ITI following ratings to precede the next trial to allow EMG activity to return to baseline.

3. Facial electromyography

3.1. Data acquisition and filtering guidelines (based on previous protocols^{27,34})

3.1.1. Use software to apply filtering steps either in real-time or offline. Typical filtering steps include a comb band stop filter to filter out potential noise from AC power (50/60 Hz), followed by smoothing and rectification.

NOTE: Initial basic filtering steps may be set on EMG amplifiers (e.g., a high pass filter of 10 Hz and a low pass filter of 500 Hz or 1000 Hz).

3.2. Electrode application (based on previous protocols^{27,34})

3.2.1. Briefly describe the application process to the participant. Use neutral words ("sensor") instead of potentially anxiety-evoking words ("electrode")³⁴.

3.2.1.1. Decide what information to tell the participants regarding the purpose of the sensors.

NOTE: In the current studies, participants were told sensors would measure muscle and sweat activity during the session.

3.2.2. Clean the participants' skin prior to electrode application.

3.2.2.1. Use water to wipe clean the areas in which sensors will be applied.

3.2.2.2. Use an exfoliant scrub to lightly abrade the same areas. Use caution to prevent major skin irritation, though minor irritation is likely to occur.

3.2.3. Use electrode pairs consisting of two 4 mm shielded bipolar recording electrodes plus one monopolar reference electrode.

3.2.3.1. Apply adhesive collars to the electrodes such that they adhere to the skin.

3.2.3.2. Once collars adhere to the outer rim of the electrodes, fill sensors with a conductive electrode gel, taking care to prevent the formation of air bubbles.

3.2.4. Place electrode pairs parallel to the muscle(s) of interest and perpendicular to potential sources of noise, such as other muscles³⁴.

3.2.4.1. Corrugator: Affix one electrode directly above the eyebrow along an imaginary vertical line that traverses the inner corner of the eye. Place the second electrode 1 cm lateral and slightly superior to the first, along the border of the eyebrow.

3.2.4.2. Zygomatic: Place the first sensor midway along an imaginary line that connects the upper ear (where the ear meets the skull) and the corner of the mouth. Place the second electrode 1 cm medial (towards the mouth). Take care to avoid the masseter muscle.

3.2.4.3. Use an 8 mm unshielded, monopolar recording electrode as a reference electrode. Place the electrode in the middle of the forehead, equidistant (above) the inner brows and (below) the hairline.

3.2.4.4. Ensure that electrode wires are placed such that they do not impede vision. Use medical tape to ensure long-term adherence of the electrodes to skin and reduce noise/artifacts due to cord movement.

3.2.5. Determine the quality of electrode application with an impedance monitor. Acceptable impedance levels are below 20 k Ω . If electrodes need to be reapplied to reach appropriate impedance levels, use a clean pair of electrodes.

4. Task procedure

4.1. General order

4.1.1. Following sensor application, complete task(s). If using more than one task,

counterbalance order across participants.

4.1.2. Ensure that participants are seated comfortably to minimize extraneous movement that may introduce movement artifacts³⁴.

4.2. Experienced touch task

4.2.1. Seat participants in front of computer with the to-be-touched arm extended laterally, resting comfortably (e.g., on a cushion).

NOTE: It is recommended to apply touch to the arm that is not being used for self-reported ratings in order to minimize potential movement artifacts in the EMG signal.

4.2.2. Occlude view of the arm from the participant either using a curtain separator³¹ or goggles that occlude lateral vision (**Figure 1**³²)³⁵.

4.2.3. Instruct the participant to focus on how the touch makes them feel.

4.2.4. Vary touch location to avoid CT fatigue³⁶.

4.2.5. Administer touch using a 75 mm goat hair brush applied to designated section(s) marked on the arm (and palm). Alternatively, apply touch using a force-controlled robot³⁷.

4.2.6. Use consistent touch administration direction, e.g., back-and-forth (distal-to-proximal, then proximal to distal) or single direction (proximal-to-distal only)

4.3. Observed touch task

4.3.1. Seat participant in front of the computer that will display the videos.

4.3.2. Instruct the participant that they will have to rate how the video made them feel.

4.3.3. Ensure that the participant is out of view of the experimenter³⁴.

5. Data cleaning and analysis

5.1. To assess the mean EMG activation to a specific touch stimulus type, compare the response to the touch stimulus to the preceding baseline, i.e. [mean activation during 6 s touch stimulation] – [mean activation during 1 s prestimulus “baseline”], as suggested by Fridlund and Cacioppo³⁴.

5.1.1. Average responses for each touch stimulus type (CT-optimal, non-optimal and, if appropriate, each location (arm/palm).

5.1.2. Do this for each muscle (corrugator, zygomatic) and self-report rating (pleasantness, intensity) individually.

5.2. To obtain a more sensitive time course, compute mean EMG activation during smaller time intervals (e.g., 700 ms; see **Figure 5**³²). Subtract the same 1 s baseline from all intervals to remove baseline EMG activity.

NOTE: Prior to analysis, it is recommended to have data manually checked by raters blinded to touch conditions to eliminate trials with artifactual activations³⁴.

REPRESENTATIVE RESULTS:

CT-optimal touch elicits distinct EMG responses compared to fast non-optimal touch across modalities

The first experiment addressed whether differential EMG reactivity could be detected in response to CT-optimal (3 cm/s) and fast non-optimal (30 cm/s) tactile stimulation that was directly experienced (**Figure 3**) or merely observed (**Figure 2** and **Figure 3**)³¹.

Experienced CT-optimal touch was rated as more pleasant than non-optimal touch ($F(1,28) = 32.2$; $p < 0.001$; **Figure 3A**) regardless of touch location ($p = 0.063$; velocity x location: $p = 0.32$). Similarly, observed CT-optimal touch was rated as more pleasant than non-optimal touch (touch velocity: $F(1,28) = 47.5$; $p < 0.001$; touch type: $F(2,56) = 6.09$, $p = 0.004$; type x velocity interaction $F(2,56) = 5.87$, $p = 0.005$). CT-optimal touch to the arm was rated as more pleasant than touch to the palm ($p = 0.024$) and non-social touch (e.g., touch to the wooden arm; $p = 0.001$). Fast non-optimal touch was always rated as more intense (**Figure 3B**), regardless of whether the touch was experienced (touch velocity: $F(1,28) = 34.3$, $p < 0.001$; touch location: $p = 0.28$; velocity x location interaction: $p = 0.64$) or observed (touch velocity: $F(1,28) = 35.1$, $p < 0.001$; touch type: $p = 0.40$; velocity x type interaction: $p = 0.39$).

Experienced fast, non-optimal touch elicited robust corrugator reactivity that was mitigated by recruitment of CT-afferents during CT-optimal touch (effect of touch velocity: $F(1,28) = 4.84$, $p = 0.036$; effect of touch location: $p = 0.93$; touch velocity x location interaction: $p = 0.42$; **Figure 3C**). Corrugator response significantly differed between CT-optimal and non-optimal touch for touch to the arm ($p = 0.050$) but only trend level effects were seen for touch to the palm ($p = 0.092$). There was no main effect of touch velocity ($p = 0.11$) or type ($p = 0.79$) on corrugator reactivity to observed touch, but there was a touch velocity x type interaction ($F(2,56) = 3.80$, $p = 0.028$). Post hoc tests revealed that fast non-optimal touch elicited greater corrugator reactivity than CT-optimal touch particularly for videos of touch to the arm ($p = 0.007$), but not touch to the palm ($p = 0.13$) or non-social touch ($p = 0.25$). Zygomatic activity was not significantly affected by experienced touch (effect of touch velocity: $p = 0.15$; effect of touch type: $p = 0.73$; touch velocity x type interaction: $p = 0.63$; **Figure 3D**), nor observed touch (main effect of touch velocity: $p = 0.37$; main effect of touch type: $p = 0.84$; touch velocity x type interaction: $p = 0.23$).

CT-optimal touch elicits EMG responses distinct from slow non-optimal touch

Experiment 2 assessed whether slow non-optimal (0.3 cm/s) would elicit similar responses as fast

non-optimal (30 cm/s)³². We found that slow non-optimal touch was rated as less pleasant (**Figure 4A**) and less intense (**Figure 4B**) than CT-optimal touch. Similar to fast non-optimal touch, slow non-optimal touch elicited robust corrugator activity that was attenuated by CT-optimal touch (effect of touch velocity: $F(1,83) = 9.723, p = 0.002$; **Figure 4C**). There was no effect of touch on zygomatic activity ($p = 0.35$; **Figure 4D**).

We next assessed the time course of EMG responses. During the first 700 ms, a window putatively free of CT input, there was no difference in corrugator reactivity ($-0.031 \pm 0.06 \mu V$ and $-0.017 \pm 0.49 \mu V$, $p_{Bon} = 0.98$; **Figure 5A**). However, over the next 5.6 s, corrugator reactivity in response to CT optimal touch decreased gradually, whereas it gradually increased in response to slow non-optimal touch: during interval 2, the corrugator reactivity was marginally lower for CT optimal touch than non-optimal touch ($p_{Bon} = 0.071$). During intervals 3, 5, 6, 7 and 8, the corrugator reactivity was significantly lower during CT optimal touch than during non-optimal touch ($p_{Bon} < 0.034$; **Figure 5A**). This pattern was absent in analysis of zygomatic reactivity ($p = 0.83$; **Figure 5B**).

FIGURE AND TABLE LEGENDS:

Figure 1: Example of experimental setup for the Experienced Touch task. Seat the participant in front of the computer with their arm extended laterally, comfortably resting on a cushion. If obtaining self-report ratings, it is recommended to apply touch to the arm that is not used to provide ratings to avoid potential movement artifacts from contaminating the EMG signal. The arm should be occluded from view of the participant^{35,39}, either with customized glasses, as above, or using a curtain separator. This figure is adapted from Ree et al.³²

Figure 2: Example of touch stimuli used in the Observed Touch task. The observed touch task included 6 s videos of touch to the (A) CT-rich arm, (B) CT-lacking palm, and (C) non-social touch to a wooden arm.

Figure 3: CT-optimal touch elicits distinct responses compared to fast non-optimal touch across modalities. (A) CT-optimal touch (3 cm/s) is consistently rated as more pleasant than fast non-optimal touch (30 cm/s) across both tasks. Experienced touch is rated as most pleasant, followed by social (arm, palm) observed touch, then non-social touch (e.g. touch to a wooden arm). (B) CT-optimal touch is (3 cm/s) rated as less intense across modalities, regardless of modality or social content. (C) Fast non-optimal touch (30 cm/s) elicits more corrugator reactivity than CT-optimal touch (3 cm/s). This difference is most robust for touch to the CT-rich arm. (D) CT-optimal touch (3 cm/s) marginally increases zygomatic reactivity, though this does not reach significance for any modality or location. Bars and errors bars represent mean and standard error of the mean; * $p < 0.05$ effect of velocity. This figure is adapted from Mayo et al.³¹

Figure 4: CT-optimal touch (3 cm/s) elicits distinct responses as compared to slow non-optimal touch (0.3 cm/s). (A) CT-optimal touch (3 cm/s) is rated as more pleasant than slow non-optimal touch (0.3 cm/s). (B) CT-optimal touch (3 cm/s) is rated as more intense than slow non-optimal touch (0.3 cm/s). (C) Mean corrugator reactivity in response to CT-optimal (3 cm/s) is reduced compared to slow non-optimal (0.3 cm/s). (D) Touch does not significantly influence zygomatic

reactivity. Bars and error bars represent means and standard error of the mean; $*p < 0.05$. This figure is adapted from Ree et al.³²

Figure 5: Corrugator responses to CT-optimal touch are temporally specific. (A) When binned in intervals of 700 ms, CT-optimal touch elicits significantly less corrugator reactivity. The exception is in the first 700 ms, which is putatively free of CT input due to the slower conduction velocity of these unmyelinated afferents. (B) Zygomatic reactivity is not significantly different in response to optimal or slow non-optimal touch at any of the time points. Dots represent means and bars represent standard errors of the mean. This figure is adapted from Ree et al.³²

Table 1: Summary of Experimental Designs. In the Experienced Touch task of Experiment 1, touch was delivered at CT-optimal (3 cm/s) or fast non-optimal (30 cm/s) velocities to hairy (arm) and glabrous (palm) skin. The Observed Touch instead included videos of touch delivered to the arm, palm, or to a wooden arm (e.g., non-social) at the same touch velocities. The “non-social” condition was included to control for potential responses elicited by low-level periodicity information encoded in the movement¹⁷, and determine the relevance of social content³⁸ on ratings and EMG responses. Results were analyzed using repeated measures analysis of variance (ANOVA) with touch velocity and touch type as within-subjects factors. A post-hoc power analysis based on Experiment 1 suggests at least 22 individuals should be included to achieve similar effects. In Experiment 2, touch was delivered to the arm at CT-optimal (3 cm/s) or slow non-optimal (0.3 cm/s) velocities. Touch was delivered for a total of 2min, but here we only report on the first 6.3 s in order to compare results to Experiment 1. Each velocity was repeated twice. In all experiments, self-reported ratings of the affective quality (e.g., pleasantness) and discriminative aspects (e.g., intensity) were assessed¹⁰.

DISCUSSION:

Here, we report on the use of facial electromyography (EMG) as a method to study affective responses to observed and experienced touch. Previously, many studies have focused on the use of self-report ratings to characterize the affective quality of touch. Touch that optimally activates CT afferents (e.g., 1-10 cm/s) is consistently rated as more pleasant than either faster or slower touch velocities¹⁰. In contrast, ratings of intensity seem to track with velocity, with faster touch velocities rated as more intense, likely mediated via A β fibers³⁷. Using two separate datasets, we show that both fast and slow non-optimal touch elicit robust corrugator reactivity that is attenuated during CT-optimal touch. Thus, we find that touch that is rated as less pleasant (e.g., non-optimal touch) also increases corrugator activity, suggestive of enhanced negative affect. In addition, we find that responses are similar across modalities. That is, both observed and experienced touch elicit similar facial muscle activity. In both modalities, these effects were only significant for touch to the arm, and not the palm or a wooden arm. Thus, while self-reported ratings of experienced and observed affective touch are similar regardless of location (arm, palm), facial EMG only significantly differentiates between touch velocities applied to the CT-rich arm, and not the CT-fiber-lacking palm.

The results further show that the temporal sensitivity of facial EMG yields insight into emotional processing that cannot be obtained solely by self-report. Namely, we found that corrugator

reactivity to CT-optimal touch becomes evident at a timescale that coincides with known conduction velocities of CT afferents^{1,12}. Thus, in the initial 700 ms of touch, which are believed to be dominated by A β activation, there is no difference in EMG activation between the two touch velocities. However, the distinction between CT-optimal and non-optimal touch becomes evident following the first 700 ms, consistent with the previously reported temporal time lag of CT-afferents^{2,12}. Hence, facial EMG is able to detect changes in affective responses to touch that occur with a temporal specificity that is likely inaccessible via verbal reporting.

Across both studies, we find that CT-optimal and non-optimal touch can be distinguished via corrugator activity. However, we did not find an effect of touch on zygomatic reactivity, which is in contrast to previous reports⁴⁰. One potential reason for the discrepancies between the current data and previous findings include methodological differences such as inclusion of a post-touch period in the analysis. Thus, we stress the importance of methodological considerations such as the length of the touch stimulation and inter-trial intervals when designing these experiments.

There are several factors that should be considered when assessing affective reactions to touch. One potential area of concern is the gender of the experimenter (and thus, toucher) to that of the participant, as well as the relationship, if any, between the two⁴¹. Moreover, one should ensure that participants are precluded from viewing the experimenter and touch application, as visual processing of touch can influence the perception of touch^{35,39}. There are also concerns to weigh during task design. For instance, it is important to consider the potential for order effects, both in regards to touch stimuli presentation (e.g. discussed in⁴²) or touch location⁴³. If several touch repetitions are used, one may want to vary touch location to avoid CT fatigue³⁶. Here, we used a brush to apply touch to compare to previous studies¹⁷, though it is possible that EMG responses may be different using more ecologically valid methods (e.g., touch by hand).

While we believe the use of facial EMG will be of a great benefit to the field of affective touch, there are limitations to this methodology that warrant consideration. Training is required to learn how to apply the electrodes correctly, producing an increased burden on the experimenter on the outset of experimental planning. Excessive movement, talking, or other environmental factors present during the experiment may cause artifacts in the EMG signal, thus constraining some experimental design features. Moreover, the application of electrodes to the face may elicit an attempt to discern the purpose of the study. As such, one must consider what information to tell the participant regarding not only the purpose of the experiment, but also the use of the electrodes during the experiment. In the current experiments, the participants were told that the purpose of the study was the investigate decision-making and perceptions of various sensations³² or reactions to social interactions³¹. In both cases, participants were told that the electrodes would measure sweat and muscle activity and were fully debriefed following the conclusion of the experiment. These concerns and others are addressed thoroughly in Fridlund and Cacioppo 1986³⁴.

In sum, we demonstrate that facial EMG is a reliable, robust, and informative method to assess the affective valence of tactile stimulation. This method provides a means to implicitly assess responses to tactile stimulation independent of verbal reports, paving the way for studies in

infants and young children, cross-cultural comparisons, investigations of clinical conditions, and other situations in which semantics and language may otherwise preclude scientific exploration.

ACKNOWLEDGMENTS:

The authors are grateful to Dr. Margaret Wardle for her exceptional training and technical assistance. This work was funded in part by Swedish Research Council grant FYF-2013-687 (IM).

DISCLOSURES:

The authors have nothing to disclose

REFERENCES:

- 1 Abaira, V. E., Ginty, D. D. The sensory neurons of touch. *Neuron*. **79** (4), 618-639 (2013).
- 2 Olausson, H., Wessberg, J., Morrison, I., McGlone, F., Vallbo, A. The neurophysiology of unmyelinated tactile afferents. *Neuroscience and Biobehavioral Reviews*. **34** (2), 185-191 (2010).
- 3 Gallace, A., Spence, C. The science of interpersonal touch: an overview. *Neuroscience and Biobehavioral Reviews*. **34** (2), 246-259 (2010).
- 4 Morrison, I., Loken, L. S., Olausson, H. The skin as a social organ. *Experimental Brain Research*. **204** (3), 305-314 (2010).
- 5 Morrison, I. et al. Reduced C-afferent fibre density affects perceived pleasantness and empathy for touch. *Brain: A Journal of Neurology*. **134** (Pt 4), 1116-1126 (2011).
- 6 Olausson, H. et al. Unmyelinated tactile afferents signal touch and project to insular cortex. *Nature Neuroscience*. **5** (9), 900-904 (2002).
- 7 Croy, I., Sehlstedt, I., Wasling, H. B., Ackerley, R., Olausson, H. Gentle touch perception: From early childhood to adolescence. *Developmental Cognitive Neuroscience*. 10.1016/j.dcn.2017.07.009 (2017).
- 8 Croy, I., Geide, H., Paulus, M., Weidner, K., Olausson, H. Affective touch awareness in mental health and disease relates to autistic traits - An explorative neurophysiological investigation. *Psychiatry Research*. **245**, 491-496 (2016).
- 9 Crucianelli, L., Cardi, V., Treasure, J., Jenkinson, P. M., Fotopoulou, A. The perception of affective touch in anorexia nervosa. *Psychiatry Research*. **239**, 72-78 (2016).
- 10 Loken, L. S., Wessberg, J., Morrison, I., McGlone, F., Olausson, H. Coding of pleasant touch by unmyelinated afferents in humans. *Nature Neuroscience*. **12** (5), 547-548 (2009).
- 11 Ackerley, R. et al. Human C-Tactile Afferents Are Tuned to the Temperature of a Skin- Stroking Caress. *The Journal of Neuroscience*. **34** (8), 2879-2883 (2014).
- 12 Ackerley, R., Eriksson, E., Wessberg, J. Ultra-late EEG potential evoked by preferential activation of unmyelinated tactile afferents in human hairy skin. *Neuroscience Letters*. **535**, 62-66 (2013).
- 13 Morrison, I. ALE meta-analysis reveals dissociable networks for affective and discriminative aspects of touch. *Human Brain Mapping*. **37** (4), 1308-1320 (2016).
- 14 Case, L. K. et al. Encoding of Touch Intensity But Not Pleasantness in Human Primary Somatosensory Cortex. *The Journal of Neuroscience*. **36** (21), 5850-5860 (2016).
- 15 Case, L. K. et al. Touch Perception Altered by Chronic Pain and by Opioid Blockade. *eNeuro*. **3** (1) (2016).

- 530 16 Davidovic, M., Starck, G., Olausson, H. Processing of affective and emotionally neutral
531 tactile stimuli in the insular cortex. *Developmental Cognitive Neuroscience*.
532 10.1016/j.dcn.2017.12.006 (2017).
- 533 17 Morrison, I., Bjornsdotter, M., Olausson, H. Vicarious responses to social touch in
534 posterior insular cortex are tuned to pleasant caressing speeds. *The Journal of*
535 *Neuroscience*. **31** (26), 9554-9562 (2011).
- 536 18 Nisbett, R. E., Wilson, T. D. Telling more than we can know: Verbal reports on mental
537 processes. *Psychological Review*. **84** (3), 231-259 (1977).
- 538 19 Sato, H., Kawahara, J. Selective bias in retrospective self-reports of negative mood states.
539 *Anxiety, Stress, and Coping*. **24** (4), 359-367 (2011).
- 540 20 Robinson, M. D., Clore, G. L. Belief and feeling: evidence for an accessibility model of
541 emotional self-report. *Psychological Bulletin*. **128** (6), 934-960 (2002).
- 542 21 Cascio, C. J. et al. Perceptual and neural response to affective tactile texture stimulation
543 in adults with autism spectrum disorders. *Autism Research*. **5** (4), 231-244 (2012).
- 544 22 Tager-Flusberg, H., Paul, R., Lord, C. Language and communication in autism. *Handbook*
545 *of Autism and Pervasive Developmental Disorders*. **1**, 335-364 (2005).
- 546 23 Lang, P. J., Greenwald, M. K., Bradley, M. M., Hamm, A. O. Looking at pictures: affective,
547 facial, visceral, and behavioral reactions. *Psychophysiology*. **30** (3), 261-273 (1993).
- 548 24 Rozga, A., King, T. Z., Vuduc, R. W., Robins, D. L. Undifferentiated facial electromyography
549 responses to dynamic, audio-visual emotion displays in individuals with autism spectrum
550 disorders. *Developmental Science*. **16** (4), 499-514 (2013).
- 551 25 Joussain, P., Ferdenzi, C., Djordjevic, J., Bensafi, M. Relationship Between
552 Psychophysiological Responses to Aversive Odors and Nutritional Status During Normal
553 Aging. *Chemical Senses*. **42** (6), 465-472 (2017).
- 554 26 Horio, T. EMG activities of facial and chewing muscles of human adults in response to
555 taste stimuli. *Perceptual and Motor Skills*. **97** (1), 289-298 (2003).
- 556 27 Tassinari, L. G., Cacioppo, J. T., Vanman, E. J. in *Handbook of Psychophysiology*, eds. Gary
557 Berntson, John T. Cacioppo, Louis G. Tassinari. 267-300. Cambridge University Press,
558 Cambridge, UK (2007).
- 559 28 Larsen, J. T., Norris, C. J., Cacioppo, J. T. Effects of positive and negative affect on
560 electromyographic activity over zygomaticus major and corrugator supercilii.
561 *Psychophysiology*. **40** (5), 776-785 (2003).
- 562 29 Dimberg, U., Thunberg, M., Grunedal, S. Facial reactions to emotional stimuli:
563 Automatically controlled emotional responses. *Cognition and Emotion*. **16** (4), 449-471
564 (2002).
- 565 30 Dimberg, U., Thunberg, M., Elmehed, K. Unconscious facial reactions to emotional facial
566 expressions. *Psychological Science*. **11** (1), 86-89 (2000).
- 567 31 Mayo, L. M., Lindé, J., Olausson, H., Heilig, M., Morrison, I. Putting a good face on touch:
568 Facial expression reflects the affective valence of caress-like touch across modalities.
569 *Biological Psychology*. <https://doi.org/10.1016/j.biopsycho.2018.07.001> (2018).
- 570 32 Ree, A., Mayo, L. M., Leknes, S., Sailer, U. Touch targeting C-tactile afferent fibers has a
571 unique physiological pattern: a combined electrodermal and facial electromyography
572 study. *Biological Psychology*. 10.1016/j.biopsycho.2018.11.006 (2018).
- 573 33 Kreuder, A. K. et al. How the brain codes intimacy: The neurobiological substrates of

romantic touch. *Human Brain Mapping*. **38** (9), 4525-4534 (2017).

34 Fridlund, A. J., Cacioppo, J. T. Guidelines for human electromyographic research. *Psychophysiology*. **23** (5), 567-589 (1986).

35 Tipper, S. P. et al. Vision influences tactile perception without proprioceptive orienting. *Neuroreport*. **9** (8), 1741-1744 (1998).

36 Vallbo, Å. B., Olausson, H., Wessberg, J. Unmyelinated Afferents Constitute a Second System Coding Tactile Stimuli of the Human Hairy Skin. *Journal of Neurophysiology*. **81** (6), 2753-2763 (1999).

37 Triscoli, C., Olausson, H., Sailer, U., Ignell, H., Croy, I. CT-optimized skin stroking delivered by hand or robot is comparable. *Frontiers in Behavioral Neuroscience*. **7**, 208 (2013).

38 Croy, I. et al. Interpersonal stroking touch is targeted to C tactile afferent activation. *Behavioural Brain Research*. **297**, 37-40 (2016).


39 Keizer, A., de Jong, J. R., Bartlema, L., Dijkerman, C. Visual perception of the arm manipulates the experienced pleasantness of touch. *Developmental Cognitive Neuroscience*. <https://doi.org/10.1016/j.dcn.2017.09.004> (2017).

40 Pawling, R., Cannon, P. R., McGlone, F. P., Walker, S. C. C-tactile afferent stimulating touch carries a positive affective value. *PloS One*. **12** (3), e0173457 (2017).


41 Scheele, D. et al. An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits. *Neuropsychopharmacology*. **39** (9), 2078-2085 (2014).


42 Ackerley, R., Saar, K., McGlone, F., Backlund Wasling, H. Quantifying the sensory and emotional perception of touch: differences between glabrous and hairy skin. *Frontiers in Behavioral Neuroscience*. **8** (34) (2014).

43 Loken, L. S., Evert, M., Wessberg, J. Pleasantness of touch in human glabrous and hairy skin: order effects on affective ratings. *Brain Research*. **1417**, 9-15 (2011).












A






B








Click here to access/download
Video or Animated Figure
ObsTouch_Arm.avi







Click here to access/download
Video or Animated Figure
ObsTouch_Palm.avi





Click here to access/download
Video or Animated Figure
ObsTouch_NonSocial.avi



	Study N	Velocity		Touch	Touch	Number of	
	(M/F)	CT-optimal	Non-optimal	Location/Type	Duration	repetitions	
Experiment 1							
<i>Experienced Touch</i>	30 (17/13)	3 cm/s	30 cm/s	Arm, palm	6 sec	8 x velocity, location (32 total)	
<i>Observed Touch</i>	30 (17/13)	3 cm/s	30 cm/s	Arm, palm, non-social	6 sec	4 x location, type (24 total)	
Experiment 2							
<i>Experienced Touch</i>	44 (17/27)	3 cm/s	0.3 cm/s	Arm	6.3 sec (of 2min)	2 x velocity (total)	(4

Name of Material/ Equipment	Company	Catalog Number
4mm Ag-AgCl sheilded reusable electrodes	Biopac	EL654
75mm goat hair brush	IN-EX Color AB	77062
8mm Ag-AgCl unsheilded reusable electrode	Biopac	
Acqknowledge software	Biopac	ACK100W
Adhesive collars	Biopac	ADD204
Cables	Biopac	BN-EL30-LEAD3; LEAD2
Electro-gel	Biopac	GEL100
EMG aplifier x 2	Biopac	BN-EMG2
El-Prep	Biopac	ELPREP
MP160 data acqusition system	Biopac	MP160WSW
Presentation software	Neurobehavioral systems	

Comments/Description

Touch application; <https://www.in-exfarg.se>

Used for application of filtering steps, analysis

LEAD3 includes ground, LEAD2 is only bipolar recording electrodes

Facial exfoliant

Task presentation software



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Recording more than one can tell: Using facial electromyography to assess facial muscle reactions to experienced and observed touch in humans
Author(s):	Anbjørn Ree, India Morrison, Håkan Olausson, Uta Sailer, Markus Heilig, Leah M. Mayo

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Leah M. Mayo		
Department:	Center for Social and Affective Neuroscience, Dept. of Clinical & Experimental Medicine		
Institution:	Linköping University		
Title:	Postdoctoral Research Fellow		
Signature:		Date:	10-10-2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Editorial comments:

Changes to be made by the author(s) regarding the manuscript:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

We have thoroughly read the manuscript and corrected any mistakes.

2. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

We have obtained formal permission to re-use the figures. This is indicated in the manuscript and information will be submitted with the manuscript.

3. Figures 2-4: Please define the error bars and asterisk symbols in the figure legend.

This has been updated as requested.

4. Please revise the title to be more concise and avoid the use of colon.

The title has been revised accordingly.

5. Keywords: Please provide at least 6 keywords or phrases.

We have added an additional keyword to bring the total to 6

6. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names. Examples of commercial sounding language in your manuscript are: Biopac,

We have removed the word "Biopac" from the manuscript.

7. Please include an ethics statement before the numbered protocol steps, indicating that the protocol follows the guidelines of your institution's human research ethics committee.

A statement of ethical approval has been added.

8. Please revise the protocol to contain only action items that direct the reader to do something (e.g., "Do this," "Ensure that," etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as "could be," "should be," and "would be" throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a "Note." Please include all safety procedures and use of hoods, etc. However, notes should be used sparingly and actions should be described in the imperative tense wherever possible. Please move the discussion about the protocol to the Discussion.

We have revised the protocol to include only action items and removed unwanted language as requested.

9. The Protocol should be made up almost entirely of discrete steps without large paragraphs of text between sections. Please simplify the Protocol so that individual steps contain only 2-3 actions per step and a maximum of 4 sentences per step. Use sub-steps as necessary. Please move the discussion about the protocol to the Discussion.

We have modified our protocol to include only discrete steps.

10. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.

We have highlighted the essential steps of the protocol.

11. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.

We have highlighted complete sentences.

12. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

We have included all relevant details.

13. Lines 116, 321, 330, etc.: Please note that manuscripts that are under review should not be listed.

The manuscript has since been accepted and the reference is updated to denote this.

14. JoVE articles are focused on the methods and the protocol, thus the discussion should be similarly focused. Please revise the Discussion to explicitly cover the following in detail in 3-6 paragraphs with citations:

- a) Critical steps within the protocol
- b) Any modifications and troubleshooting of the technique
- c) Any limitations of the technique
- d) The significance with respect to existing methods
- e) Any future applications of the technique

We have modified our Discussion as requested.

15. References: Please do not abbreviate journal titles. If there are six or more authors, list the first author and then “et al.”.

We have updated our references accordingly.

16. Please ensure that the references appear as the following: [Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. Source. Volume (Issue), FirstPage – LastPage (YEAR).] For more than 6 authors, list only the first author then et al. See the example below:

Bedford, C.D., Harris, R.N., Howd, R.A., Goff, D.A., Koolpe, G.A. Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. Journal of Medicinal Chemistry. 32 (2), 493-503 (1998).

We have updated our references according to the provided format.

17. Table of Materials: Please sort the items in alphabetical order according to the Name of Material/Equipment.

We have sorted the table as requested

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

This manuscript presents a new method for assessing emotional responses to affective touch using facial electromyography (EMG). The authors present two studies that both show that facial EMG of the corrugator supercilii muscle is sensitive to touch at CT-optimal and non-optimal frequencies, and that touch at the CT-optimal frequency suppresses corrugator activity. The authors suggest this method may be more effective at measuring affective responses to touch than self-report measures in some populations. The manuscript is very well written, clear, and thorough, and describes a method that will be useful to researchers studying affective responses to touch. Suggestions for improvement of the manuscript are below; these are mostly minor points for clarity.

Major Concerns:

One important aspect of this manuscript is the relationship between self-report and electromyographic measures, as the authors suggest EMG may be a more usable measure of emotional reactivity in certain populations. It would strengthen the manuscript to spend more time describing the relationship between self-report and EMG measures in the results (from both study 1 and study 2), rather than just mentioning them in the legend for figure 3D.

We have expanded our discussion of the relationship between self-report and EMG in the discussion, as suggested by the reviewer.

Further, it's clear EMG may be useful for populations with difficulty verbalizing self-report measures, but are the authors suggesting it is a more sensitive measure of emotional reactivity? Or does it merely have broader potential applications than self report? What about it's translational potential; has it been used to assess affect in animal models?

We appreciate these important points brought forth by the reviewer. At this stage, we cannot say for certain that this measure is more sensitive or if it is assessing a distinct dimension of affective processing. However, we know from other studies that interventions such as drug administration [1] or stress exposure [2] can influence EMG responses independent of changes in self-report ratings. Thus, as a method, EMG may be useful in tapping into certain facets of affective processing that may not be accessible via self-report. The role of facial expressions in human (and animal) behavior has recently gained much interest (e.g. [3]) and we are interested in the potential translational opportunities it puts forth.

Minor Concerns:

Abstract

Excellent, concise abstract.

Introduction

Good description of the CT-afferent literature that is appropriately detailed. The background information on populations with dysregulated CT-afferent signaling could be moved to the discussion, as this method is being presented in healthy populations and that would be a future application of the protocol.

We appreciate the reviewer's suggestion. Unfortunately, we have been asked to limit our discussion and are thus unable to move the section as requested.

A couple of sentences introducing the two experiments that validated the methods could be added here to improve the flow of the manuscript.

We have added this to the manuscript prior to the results section.

Protocol:

A little more clarity on the control conditions would be helpful. What is the wooden hand controlling for? The authors note it is to "control for responses simply elicited by motion," but it seems as though responses to videos of the wooden hand and palm are similar. What are we to make of that? Does that mean the wooden hand condition is unnecessary?

This is an interesting point raised by the reviewer. The inclusion of the non-social condition (e.g. wooden arm) was to control for the possibility that velocity-sensitive responses may simply reflect the low-level frequency or periodicity information encoded within the videos [4]. The palm trials were included because the palm putatively lacks CT afferents, but is often engaged in social interactions (e.g. shaking of hands). Thus, we included this condition to determine whether generally social stimuli (e.g. stimuli containing two or more people) could elicit responses similar to stimuli that specifically depicted touch to an area rich in CT afferents.

We find that only the videos of touch to the CT-rich forearm at CT-optimal and non-optimal velocities can elicit differential corrugator activation. In the palm and non-social conditions, there was no significant difference between CT-optimal and non-optimal touch velocities. However, all CT-optimal videos were rated as more pleasant than non-optimal. As such, EMG of the corrugator muscle appears to be specifically activated in response to the observation of touch that potentially activates CT afferents, even if other stimuli (e.g. touch to the palm) are rated as pleasant. Thus, we do believe that inclusion of all three types of touch stimuli are informative.

The authors note the experimenters might want to occlude the participant's arm from view; it should be explained why this might be done.

We have included the following statement: "Occlude view of the arm from the participant either using a curtain separator or goggles that occlude lateral vision to avoid influence of vision on tactile perception(e.g. [6])"

Results

The sample sizes for each study should be reported in the results.

We apologize for this oversight; we have included a table that denotes task information and sample sizes. Specifically, 30 individuals were in Experiment 1 and 44 individuals in Experiment 2.

Discussion

It should be added to the discussion that the identity of the person doing the touch (romantic partner, friend, stranger) may influence affective responses.

This is an important point raised by the reviewer which we have now included in the discussion.

Reviewer #2:

Minor change

- Please go through the text: Some of the sentences seem incomplete because (1) the words are in the wrong order and/or repeated or (2) the reference style.

We have now thoroughly proofread the manuscript to correct these errors.

Major changes

As this is an invited manuscript, because of its novel methodology:

- Please do not refer to Experiment 1 and 2 from the "original paper(s)". This JoVE manuscript is original in itself (so it shouldn't matter that one experiment is still under review).

We have removed this wording from the manuscript

- Please reduce the Result section to only describing the methodology.

We have attempted to reduce the result section to include only the relevant information.

- Please reduce the Discussion of the results (findings), and increase the discussion of the methodology used (e.g. in relation to data validity and reliability, as data were collected in two ways - EMB and self-report).

We have made an effort to modify the discussion as requested.

Reviewer #3:

The manuscript describes a novel method to measure the affective component of CT-fiber activating touch, which the researchers replicated in two independent studies. The method described is of high scientific standard and quality, and I have no doubt that the protocol will be used a lot in the affective touch field. The protocol will help with the standardization of the affective touch application across studies and therefore it will increase comparability of studies. However, as of now, the manuscript lacks details in the method and results, which are necessary for a proper replication and understanding of the methods. I address these points in detail below.

Some general questions and remarks:

*Is it correct that you find similar effects in corrugator reactivity for the experienced and observed touch condition? If so, what is the purpose of the observed touch condition? Is it a control condition?

Yes, we do find similar findings across modalities. Previous studies [4] have reported that affective touch can elicit similar brain activation patterns, regardless of whether it is directly experienced or merely observed. Thus, we wanted to determine if similar consistencies across modalities existed in EMG responses. Accordingly, we found consistent differentiation between CT-optimal and non-optimal touch in both experienced and observed conditions. However, this only applied to the trials that were directed to hairy (arm) skin and not to the glabrous (palm) skin

Can you give an explanation why you find similarities between the 2 modalities? Does this imply that the corrugator (de)activation in the CT-optimal touch is not due to CT-fiber activation?

We hypothesize that affective touch is not only driven by bottom-up activation of CT-afferents, but also involves top-down integration of information from multiple sensory modalities. This is described at length in our previous paper [7]. Unfortunately, since this paper is focused on methodology, we are precluded from discussing this interpretation within the manuscript itself, but we agree that it is an intriguing finding.

*You describe the temporal specificity of the corrugator response and list this as an advantage compared to the self-reports. Can you provide an example/ application where this temporal specificity would be useful/ helpful?

Specifically within the context of the current manuscript, we see a lack of corrugator activity early on (e.g. initial 700 ms) but then a distinct difference between CT-optimal and non-optimal touch velocities. This alone suggests that EMG can detect changes on timescales that may not be readily available via self-report. Similarly, this specificity may be useful in response to dynamic stimuli that change (e.g. randomly or contingent on response) or to stimuli that are presented briefly.

*You are comparing EMG activation between a CT-optimal and a CT-non optimal touch condition and find currogator activation during the CT-non optimal touch. The question for me is whether the CT-optimal "deactivation" of the currogator reflects a change in EMG signal or is similar to a non-activated currogator. I think this can be addressed either with additional analyses or a different control condition. My concern is that the effects are driven by the CT non-optimal touch, which would diminish the value of your method for research in clinical populations. Imagine that a clinical population is impaired in affective touch (= CT-optimal touch) processing and you want to measure corrugator activation to tap into this impairment. You probably will not see a difference in currogator activation, because the clinical population will not be impaired in the non-affective (CT non-optimal) touch processing.

This is a nice point made by the reviewer. Our response is two-fold. First, across all of our studies, we measure the mean EMG response during the stimulus (e.g. touch) compared to the immediately preceding 1sec baseline. This is due to the fact that, regardless of how well the sensors are applied/acquire data, there will always be background noise, as described in [8]. For instance, people rarely show totally zero activity in a given EMG site, as physiological

arousal/tension, movement, and activation in nearby muscles can all influence the baseline level of EMG. Thus, the realistic goal is not zero baseline EMG, but instead is to achieve a representative physiological baseline for the task at hand. As such, we find that non-optimal touch *increases* corrugator activity above this baseline. However, CT-optimal touch *reduces* corrugator activity as compared to this background EMG level.

In addition, we have proposed previously [7] that non-optimal touch may elicit a negative response as indexed by an increase in corrugator activity. However, recruitment of CT-afferents attenuates this otherwise negative response. Thus, if an individual lacked CT-afferents, we would expect to see increased corrugator reactivity to all touch, regardless of velocity. In doing so, we could conclude that the ability of CT-afferents to mitigate the negative response elicited by touch is absent. This is supported by the finding that our fast non-optimal (30 cm/s) and slow non-optimal (0.3 cm/s) elicit similar increases in corrugator reactivity, but in both experiments, this is mitigated by recruitment of CT-afferents.

We have begun to use this methodology to address these issues in clinical adolescent populations. We do find marked differences between patients and controls in regards to EMG responses to touch (but no differences in self-report ratings); however this data is not ready for publication quite yet.

*It would be helpful for the understanding of the protocol and the analyses if you would include a short paragraph at the end of your introduction with a brief summary of your study design (thus the different conditions, within- and between subject factors, dependent variables, ...) and the purpose of the different aspects of your study design.

We have included a table that addresses this concern.

Please also clarify what the purpose of the intensity rating is.

The intensity rating is included to assess more discriminative features of touch. In general, increasing velocities are rated as more intense, while the affective quality (e.g. Pleasantness) shows a U-shaped curve (e.g.[9]).

*I am missing details/ advice on participant instructions. Especially to what extend participants should know of the purpose of the study.

The participants were informed that the main purpose of the study was to investigate how sensory input could influence decision making and perceptions of various sensations. They were further told that the facial EMG electrodes would measure muscle and sweat activity throughout the study. At the start of each task, participants were instructed to think of how the touch makes them feel. We then provide more detailed information in a short "debriefing" held after the session ended. These issues are discussed in length in [8], which is also now mentioned in the discussion.

There are some cases where your writing is a bit sloppy:

*In multiple instances words are missing:

- o 2nd paragraph introduction, line 55: "with TOUCH velocities"

- o In 2.1.2 of the protocol (line 150): "such AS A visual analog scale"

- o In 2.2.1, line 169: "and non-optimal (...) TOUCH"

- o In the results section, 2nd paragraph (line 284): "slow non-optimal TOUCH fast non-optimal TOUCH"

o In the discussion section, line 362: "between CT-optimal and non-optimal TOUCH becomes..."

*In 2.2.2 (line 178) the parenthesis should be deleted.

*Please refer to the correct Figures in section 5.2, line 249.

*In 3.2.2 (line 206) "to" should be deleted in "the electrodes to in order"

*Please be consistent in how you call your tasks. Sometimes you call the experienced touch task a condition, and sometimes a task.

*Ethics statement is missing

We have corrected or removed these inconsistencies from the manuscript.

Feedback on details from the manuscript, which will improve the ease of replicability of your method:

*Section 1.1: can you advice on the minimum number of participants with a short explanation why?

We have included the following in the manuscript: "A post-hoc power analysis based on Experiment 1 suggests at least 22 individuals should be included to reach a similar effect size."

*Section 2. Stimuli and task construction: for researchers who want to use your touch method, I feel like this section would be easier to read if you'd structure this part differently. I suggest you make a paragraph where you describe the touch application and a different paragraph where you describe the task design in detail

We have made efforts to clarify these sections within the constraints of the protocol requirements (e.g. we were instructed by the editor not to discuss the task details within the protocol).

*Section 2.1.1:

o Regarding "Velocities can be distinguished using tones of differing pitches that precede the stimulation cues": it sounds very hard to remember which tone corresponds to which velocity (I can imagine an alternative, where you could also use an audio recording saying "10 cm/s" before the stimulation cues). Could you make a more general statement out of this?

We appreciate the author's comment. Since we only use two velocities, it was straightforward enough to distinguish between the anticipatory tones denoting the touch type. However, we have noted that readers are free to construct their own audio cues to their liking.

o Regarding "on an iPad or other device only in view of the experimenter": Great point! Could you add why this is important?

We have included the following statement: "Occlude view of the arm from the participant either using a curtain separator or goggles that occlude lateral vision to avoid influence of vision on tactile perception(e.g. [6])"

o Regarding "Stimuli should be of a consistent length": I find the use of the word "stimuli" confusing. A stimulus could also refer to the audio/ visual cues. I suggest you change the

wording to "stimulation" or "touch duration" (or something more appropriate). Same for section 4.3.

We have clarified this throughout.

o Regarding "the experimenter should train prior to the session": do you mean prior to every session? Or prior to data collection in general?

We only foresee training to be required prior to the first session, though this is based on the judgement of the experimenter. We have stated this more clearly within the manuscript.

o Regarding "i.e. by brushing on a scale": great point, but it is unclear how you would exactly do that. Do you mean doing the movements on the scale, or just a single push? Could you elaborate a little more on this?

We have updated the manuscript to read: "During training, use a scale to ensure that touch is delivered at a consistent pressure. To do so, apply brush strokes to the scale in a similar manner as they would to the participant. The scale readout is then used to determine if the pressure changes throughout touch administration. For instance, a pressure of 0.4N would register as 40gram on the scale."

*Section 2.1.2: you write "participants should focus on a fixation cross or blank screen on the computer screen": can you please explain why this is important?

We have modified this section, but this statement refers to the need to achieve a task-relevant physiological baseline, as described above. Since we always compare the EMG response to the immediately preceding baseline, it is imperative that the baseline be free of potential contamination by responses elicited from other sensory stimuli.

*Section 2.1.3:

o General remark: this part is confusing because it does not read as a protocol but rather like a method section. I am also missing information on total number of trials, number of trials per block, duration of trial, and number of velocity types. Because of this I am confused about the following statement "In Experiment 2, the participants were exposed to repeated tactile stimulation": in experiment 1 you didn't do that?

We have clarified this section and removed the reference portion.

o Regarding "Stimuli presentation should be (pseudo)randomized to avoid order effects": can you add a reference where they find order effects? Or alternatively can you describe how order affects your dependent variables?

We have added a section to the discussion section that highlight the potential influence of order effects.

*Section 2.2.1: You describe the delivery of touch to a wooden arm. Would you recommend this also for future studies? Please explain. I have the same question for the whole observed touch task. Do you recommend its use in future studies? Why (I think the purpose of the observed touch experiment is not completely clear)?

We appreciate the reviewer's concern and have attempted to clarify within the text.

Specifically, we used the observed touch task to determine whether affective touch requires

only “bottom up” activation of CT-afferents (e.g. the experienced condition) or if “top-down” contributions can also influence facial muscle activity in a similar manner. Based on [4], we know that information from these two modalities is indeed processed by shared neural resources. Moreover, [10] showed that people use different velocities when asked to stroke an artificial arm as compared to a human arm. Thus, we included this condition to determine if affective responses were shared across modalities and specific to social stimuli.

*Section 3.1: Regarding "It is recommended to use EMG amplifiers": this is a weird formulation. Is it possible to record EMG without an amplifier?!

We apologize for the wording. We simply meant to imply that the hardware could be used to apply basic filtering steps, while software could be used to apply additional filtering and processing. We have rewritten this accordingly.

*Section 3.2: a schematic overview of the exact placement of the electrodes would be helpful for other researchers to replicate the method.

We have included more thorough descriptions of electrode placement, as well as references that depict such placements. If the manuscript is accepted, it will be accompanied by a video that will include detailed information regarding sensor placement.

*Section 4.1:

o Does it matter which arm is used for the touch? Please explain.

In the classical microneurography studies exploring CT afferents, most recordings were obtained from the left arm [11]. However, when using facial EMG, we would recommend touch be applied to the arm that is *not* being used to provide self-report ratings. Moving the arm back and forth (between the location for touch administration and to grab the mouse) could induce movement artifacts into the EMG recordings. We have included this suggestion in the protocol.

o A picture of the set-up might be helpful for the reproduction of the methods.

We have included a picture, as requested.

*Section 4.3.:

o Does it matter what kind of brush is used? Please explain! Also explain why you use a brush instead of a hand, because in the introduction you write that CT-fibers are optimally activated with touch at skin temperature.

We used a 75mm goat hair painter’s brush, as listed in the materials list. Previous studies [4] have shown that a stiff brush (e.g. horse hair) is overall rated as less pleasant (compared to goat hair), but the pleasantness ratings for CT-optimal and non-optimal touch do not differ across brush types.

We used a brush instead of hand in an attempt to standardize the touch application, e.g. reduce variability due to skin temperature, moisture, etc. While we agree that hand touch would be more ecologically valid, we wanted the ability to standardize the touch application as much as possible, as well as be able to compare to previous studies that have used a brush to administer touch (e.g. [9, 11]). Moreover, recent evidence suggests that participants do not differ in pleasantness ratings of touch by skin or satin [12], perhaps

suggesting that we would perhaps find similar effects between touch via brush and hand. However, we agree that this is an important point and thus included it in the discussion.

o Who is applying the touch? Does it matter whether gender with participant is matched? Is the participant instructed on who is touching her?

This is an important point raised by the reviewers. The same experimenter applied the touch to all participants in a given study, thus we cannot say from our data alone whether this influences the outcome. However, other studies have found an effect of toucher gender [13], so we have included this potential issue within the discussion.

o Regarding "touch was applied to a 9cm section": is the size of the section important? Please explain

We have modified this section to remove this wording.

*Section 5: Could you please include a section with basic, general analysis steps regarding which conditions you compare and for what purpose? This helps with getting a general idea of what you can do with the tasks.

We have included basic analysis steps in the description of the tasks (Table 1), as well as reported the main effects and interactions more clearly in the results section.

o Please add dependent variable. It is unclear what "mean activation" you are referring to.

We have clarified this to state that the mean activation refers to the mean amplitude during each touch stimulus as compared to the mean amplitude during the immediately preceding 1sec baseline for the given muscle.

o Please be more specific regarding stimulus types, i.e. name them here.

We have clarified this wording throughout.

o It is unclear what the baseline in your task is, or when it is measured. Please clarify in the section where you explain your tasks.

The baseline is the background EMG signal, e.g. in the absence of any stimulus. Regardless of the quality of the sensor application/recording, there will always be a baseline EMG level that may fluctuate over time. To account for this, a "response" is quantified as the mean EMG activity during the stimulus (e.g. 6 sec) compared to the immediately preceding 1 sec baseline. Thus, the values reported are always a change from the baseline/background.

*Representative results section:

o General: If researchers want to use your method, I feel like it would be helpful for them to be able to compare their results with your results. Therefore could you please be more specific in your results section whether you report main effects, interactions, what kind of analysis you did (f.e. repeated measures Anova with which independent variables and which dependent variable). For this purpose, could you please also report the results of all the independent variables (if you haven't already done this)? And could you also add somewhere how many participants you tested for the two experiments?

This information has been added to the manuscript in the appropriate locations.

o Paragraph 1: please clarify what "socially relevant trials" are

This wording has been removed from the manuscript.

o Paragraph 2: you describe that pleasantness ratings are related to corrugator reactivity.

Could you add a correlation here?

Is a p-value missing on line 293 when describing the corrugator reactivity?

We appreciate the reviewer for point this out and have included this missing value.

*Figures: please add a description of the error-bars

We have updated the figure description to state that error bars represent the standard error of the mean.

o 3b: the size of the error bar is unclear in the CT non-optimal touch, because the y-axis only goes till -4. Please change so that other researchers who use your method can compare their results with yours.

We have corrected this as requested.

o 3c and d: please also add a similar graph for the zygomatic activation, so that other researchers can compare their results with yours.

We have added this as requested.

o 4a and b: very difficult to distinguish lines. Figure 4a and 4c show the same things, right? If yes, could you make a similar graph as in 4c for the zygomatic activation over time? And if 4a and 4c show the same results, I think 4a (and b if changed) are obsolete. The results are easier to understand from 4c.

We have modified our figures based on these requests.

References

1. Wardle, M.C. and H. de Wit, *Effects of amphetamine on reactivity to emotional stimuli*. Psychopharmacology (Berl), 2012. **220**(1): p. 143-53.
2. Mayo, L.M., A. Asratian, J. Linde, L. Holm, D. Natt, G. Augier, N. Stensson, H.A. Vecchiarelli, G. Balsevich, R.J. Aukema, B. Ghafouri, P.A. Spagnolo, F.S. Lee, M.N. Hill, and M. Heilig, *Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice*. Mol Psychiatry, 2018.
3. Crivelli, C. and A.J. Fridlund, *Facial Displays Are Tools for Social Influence*. Trends Cogn Sci, 2018. **22**(5): p. 388-399.

4. Morrison, I., M. Bjornsdotter, and H. Olausson, *Vicarious responses to social touch in posterior insular cortex are tuned to pleasant caressing speeds*. J Neurosci, 2011. **31**(26): p. 9554-62.
5. Tipper, S.P., D. Lloyd, B. Shorland, C. Dancer, L.A. Howard, and F. McGlone, *Vision influences tactile perception without proprioceptive orienting*. Neuroreport, 1998. **9**(8): p. 1741-4.
6. Keizer, A., J.R. de Jong, L. Bartlema, and C. Dijkerman, *Visual perception of the arm manipulates the experienced pleasantness of touch*. Developmental Cognitive Neuroscience, 2017.
7. Mayo, L.M., J. Lindé, H. Olausson, M. Heilig, and I. Morrison, *Putting a good face on touch: Facial expression reflects the affective valence of caress-like touch across modalities*. Biological Psychology, 2018.
8. Fridlund, A.J. and J.T. Cacioppo, *Guidelines for human electromyographic research*. Psychophysiology, 1986. **23**(5): p. 567-89.
9. Tricoli, C., H. Olausson, U. Sailer, H. Ignell, and I. Croy, *CT-optimized skin stroking delivered by hand or robot is comparable*. Front Behav Neurosci, 2013. **7**: p. 208.
10. Croy, I., A. Luong, C. Tricoli, E. Hofmann, H. Olausson, and U. Sailer, *Interpersonal stroking touch is targeted to C tactile afferent activation*. Behav Brain Res, 2016. **297**: p. 37-40.
11. Loken, L.S., J. Wessberg, I. Morrison, F. McGlone, and H. Olausson, *Coding of pleasant touch by unmyelinated afferents in humans*. Nat Neurosci, 2009. **12**(5): p. 547-8.
12. Etzi, R., M. Zampini, G. Juravle, and A. Gallace, *Emotional visual stimuli affect the evaluation of tactile stimuli presented on the arms but not the related electrodermal responses*. Exp Brain Res, 2018. **236**(12): p. 3391-3403.
13. Scheele, D., K.M. Kendrick, C. Khouri, E. Kretzer, T.E. Schlapfer, B. Stoffel-Wagner, O. Gunturkun, W. Maier, and R. Hurlmann, *An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits*. Neuropsychopharmacology, 2014. **39**(9): p. 2078-85.

ELSEVIER LICENSE TERMS AND CONDITIONS

Nov 21, 2018

This Agreement between Linköping University -- Leah Mayo ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4473690590051
License date	Nov 21, 2018
Licensed Content Publisher	Elsevier
Licensed Content Publication	Biological Psychology
Licensed Content Title	Putting a good face on touch: Facial expression reflects the affective valence of caress-like touch across modalities
Licensed Content Author	Leah M. Mayo,Johan Lindé,Håkan Olausson,Markus Heilig,India Morrison
Licensed Content Date	Sep 1, 2018
Licensed Content Volume	137
Licensed Content Issue	n/a
Licensed Content Pages	8
Start Page	83
End Page	90
Type of Use	reuse in a journal/magazine
Requestor type	author of new work
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	2
Format	electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Original figure numbers	Figure 1A, 1C, figure 2A, 2B
Title of the article	Using facial electromyography to assess facial muscle reactions to experienced and observed affective touch in humans
Publication new article is in	Journal of Visualized Experiemnts
Publisher of the new article	Other
Author of new article	Leah Mayo
Expected publication date	Jan 2019
Estimated size of new article (number of pages)	8
Requestor Location	Linköping University Hälsövägen Linköping, Non-US or Canadian Address 58431 Sweden Attn: Leah M Mayo

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.
12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.
14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.
16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.
- Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use
 - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
 - via non-commercial hosting platforms such as their institutional repository
 - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (JPA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above:

Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please

reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>.

Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.9

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

ELSEVIER LICENSE TERMS AND CONDITIONS

Nov 28, 2018

This Agreement between Linköping University -- Leah Mayo ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4477070461160
License date	Nov 27, 2018
Licensed Content Publisher	Elsevier
Licensed Content Publication	Biological Psychology
Licensed Content Title	Touch targeting C-tactile afferent fibers has a unique physiological pattern: a combined electrodermal and facial electromyography study
Licensed Content Author	Anbjørn Ree, Leah M. Mayo, Siri Leknes, Uta Sailer
Licensed Content Date	Available online 20 November 2018
Licensed Content Volume	n/a
Licensed Content Issue	n/a
Licensed Content Pages	1
Start Page	0
End Page	0
Type of Use	reuse in a journal/magazine
Requestor type	author of new work
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	3
Format	electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Original figure numbers	Figure 1, 2, 4
Title of the article	Using facial electromyography to assess facial muscle reactions to experienced and observed affective touch in humans
Publication new article is in	Journal of Visualized Experiments
Publisher of the new article	Other
Author of new article	Leah Mayo
Expected publication date	Jan 2019
Estimated size of new article (number of pages)	8
Requestor Location	Linköping University Hälsövägen
	Linköping, Non-US or Canadian Address 58431 Sweden Attn: Leah M Mayo
Publisher Tax ID	GB 494 6272 12
Total	0.00 USD
Terms and Conditions	

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.). Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
 - via their non-commercial person homepage or blog
 - by updating a preprint in arXiv or RePEc with the accepted manuscript
 - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
 - directly by providing copies to their students or to research collaborators for their personal use
 - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
 - via non-commercial hosting platforms such as their institutional repository
 - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

Subscription Articles: If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

Gold Open Access Articles: May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the

formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

Terms & Conditions applicable to all Open Access articles published with Elsevier:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:


- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

20. Other Conditions:

v1.9

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.



[Click here to access/download](#)
Supplemental Coding Files
exptouch.txt

